Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flynn Pharma Ltd.

www.flynnpharma.com

Latest From Flynn Pharma Ltd.

Pharma Faces More Probes On Generic Price Hikes in UK

As Concordia finds itself in the dock again, this time over its pricing of the essential thyroid treatment liothyronine, the UK's Competition and Markets Authority has recently opened four new investigations into "suspected abuse of dominance" concerning generics.

Legal Issues Pricing Strategies

‘Excessive Pricing’ Inquiry Widens As EC’s First Antitrust Price Probe Targets Aspen Pharma

The litany of complaints against pharmaceutical companies for imposing “excessive” prices on generic drugs is growing after the European Commission decided to pursue Aspen Pharma over price rises imposed on a range of anticancer products it acquired from GSK.

Europe Generic Drugs

UK's Crackdown On Anti-Competitive Deals Continues; Actavis In Firing Line Again

The UK's competition authority is keen to expose supposed pay-for-delay deals made by pharmaceutical firms, and is warning drug suppliers to think twice before attempting agreements that slow the entry of generic products onto the UK market.

Generic Drugs Pricing Strategies

Record Fine For Pfizer Throws Spotlight On UK Generic Pricing

Following the decision by the UK competition authority to fine Pfizer and Flynn Pharma for “unfair and excessive” pricing, generic prices are to be brought under tighter government control. But it remains to be seen how these controls will be applied in practice where companies are suspected of excessive pricing, and exactly what might constitute an “unreasonable price,” say Gustaf Duhs and Astrid Arnold.

Legal Issues Pricing Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Flynn Pharma Ltd.
  • Senior Management
  • David Walters, Dir.
  • Contact Info
  • Flynn Pharma Ltd.
    Phone: (44) 1462 458974
    Hertlands House
    Primett Rd.
    Stevenage, SG1 3EE
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register